Home > Back to Publisher > Report Information

China Chemical Pharmaceutical Industry Report, 2011

Research in China
January 1, 2012
112 Pages - SKU: RIC6792036

Abstract Table of Contents Related Reports

Countries covered: China

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last year, presenting remarkable upward momentum. The chemical pharmaceutical industry of China chiefly comprises two sub-sectors chemical API and drug preparation which show differentiated development.

China is currently the worldfs largest producer and exporter of chemical API and can produce more than 1,500 varieties with the capacity approximating 2 or 3 million tons. However, key bulk API products including vitamins and antibiotics witness overcapacity, which has resulted in low-price competition bringing adverse impact on the export of API. In Q1 2011, the API export of China increased by 39.53% year-on-year, with the export value rising 31.31% from the same period of last year, while the average export price fell 5.89% year-on-year. In particular, the average export price of Vitamin C slumped by 30%.

In comparison with chemical API sector, the chemical drug preparation sector of China enjoys higher profitability as a whole, with the gross margin in 2010 hitting 39.6% and two-fold of that of API industry. Yet, chemical preparation industry of China is still in its infancy with short R&D capability of new drugs, and therefore the production of generics is the mainstream.

The report focuses on the market size and development trend of China chemical pharmaceutical industry as well as the market scale of API and chemical preparation on the basis of the outlook for new drug R&D and market development worldwide. In addition, the market planning and new drug R&D of the leading 20 listed industrial players is also analyzed here.

Northeast Pharmaceutical Group Co., Ltd. is one of the largest Vitamin C producers in China. In 2011, the Vitamin C capacity of the company reached 25,000 tons. Currently, its investment is mainly earmarked for API. Also in 2011, it raised funds RMB2.645 billion to build Xihe-based API production base covering Vitamin C API, fosfomycin series products, L-carnitine series, and so forth.

As one of key chemical pharmaceutical companies in China, the operating revenue of. Huadong Medicine Co., Ltd in Jan.-Sep., 2011 increased by 25.51% year-on-year to RMB8.195 billion. Its holding subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, is regarded as the largest immunosuppressant producer in China.

Jiangsu Hengrui Medicine Co., Ltd is the one with the most new drugs independently developed among pharmaceutical companies in China. In 2011, it filed for the production of four new drugs with Class?T-?V and for the clinical trial of four new chemical medicines with class ?V-?X and one biological medicine with class ?\. Moreover, eleven new chemical medicines with class ?T-?X and one biological medicine with class ?\ were under clinical trial. In December 2011, Irinotecan injection developed by Jiangsu Hengrui Medicine Co. won the FDA certification and became qualified to be sold in the US market, which made it be the first of this kind among Chinese peers.

Please Note: PDF E-mail from Publisher purchase option allows up to 10 users and does not allow printing or editing. This functionality will require a Global Site License.

1. Overview of Chemical Pharmaceutical Industry: 1.1 Definition and Classification; 1.2 Industry Chain
2. Development of Global Chemical Pharmaceutical Industry: 2.1 Market Size; 2.2 Supply and Demand; 2.3 Major Countries and Regions; 2.4 Development Trend
3. Development of China Chemical Pharmaceutical Industry: 3.1 Status Quo; 3.2 Profitability; 3.3 Import & Export; 3.4 Competition; 3.5 Development Prospect; 3.6 Major Projects under Construction of Chemical Pharmaceutical Industry
4. Market Segment of Chemical Pharmaceutical in China: 4.1 Vitamins; 4.2 Antibiotics; 4.3 Antipyretic-analgesic Drugs; 4.4 Hormoues; 4.5 Antitumor Drugs; 4.6 Cardiovascular Drugs
5. API Producers in China: 5.1 Northeast Pharmaceutical Group Co., Ltd.; 5.2 North China Pharmaceutical; 5.3 Zhejiang Medicine Co., Ltd.; 5.4 Zhejiang HISUN Pharmaceuticals Co., Ltd.; 5.5 Zhejiang NHU Co., Ltd; 5.6 Shandong Xinhua Pharmaceutical Co., Ltd.; 5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd.; 5.8 Zhejiang Xianju Pharmaceutical Co., Ltd.; 5.9 Zhejiang Huahai Pharmaceuticals Co., Ltd.; 5.10 Tianjin Tianyao Pharmaceuticals Co., Ltd.
6. Chemical Preparation Manufacturers in China: 6.1 Beijing Double-crane Pharmaceutical Co., Ltd.; 6.2 Jiangsu Hengrui Medicine Co., Ltd; 6.3 Harbin Pharm. Group Sanjing Pharmaceutical Shareholding Co., Ltd.; 6.4 Guangzhou Baiyunshan Pharmaceutical; 6.5 Livzon Pharmaceutical Group; 6.6 Fosun Pharma; 6.7 Huapont Pharma.; 6.8 Hainan Haiyao Co., Ltd; 6.9 Jiangsu Nhwa Pharmaceutical Co., Ltd.; 6.10 Huadong Medicine Co., Ltd.

More China Manufacturing, Packaging & Detailing Reports

China's Pharmaceutical Industry 2011 by China Research and Intelligence Co., Ltd.
This report describes the general development of China’s pharmaceutical industry in aspects of investment, production, sales, import & export, major prices and operations. ...

Research Report on Chinese Human Vaccine Industry, 2012 by China Research and Intelligence Co., Ltd.
The research object of the report is human vaccine apart from animal vaccine. Vaccination is the most economical, effective, safe and convenient way to prevent ...

China Pharmaceutical Industry Research and Forecast to 2016 by AM Mindpower Solutions
EXECUTIVE SUMMARY The present report on “China Pharmaceutical Industry Research and Forecast to 2016” analyzes in detail the pharmaceutical industry environment with market sizing in terms ...

Freedonia Focus on Pharmaceutical Packaging: China by Freedonia Focus
This report discusses pharmaceutical packaging in China for the years 2005 and 2010, with forecasts for 2015. Topics covered include overview of products; market overview; ...

China’s Guidebook for Pharmaceutical Patent Protection by Access China Management Consulting Ltd.
China’s Guidebook for Pharmaceutical Patent Protection is an essential resource for overseas and multinational pharmaceutical companies to achieve a successful patent protection for their intellectual ...

See all reports like this >>

More China Reports

D&B Country RiskLine Report: China by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

Country Report China February 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Country Report China January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

D&B Country Report: China by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Wine - BRIC (Brazil, Russia, India, China) Industry Guide by MarketLine
Datamonitor's Wine - BRIC (Brazil, Russia, India, China) Industry Guide is an essential resource for top-level data and analysis covering the BRIC (Brazil, Russia, India, ...

See all reports like this >>

China Chemical Pharmaceutical Industry Report, 2011

Share this report

Other tasks

Research Assistance

Related Markets

Manufacturing, Packaging & Detailing Reports

Free Alert Me service